
Quarterly report 2025-Q3
added 11-14-2025
NanoVibronix EBITDA 2011-2026 | NAOV
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA NanoVibronix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.58 M | -3.44 M | -5.01 M | -5.68 M | -4.72 K | -5.15 M | -4.3 M | -3.09 M | -2.31 M | -1.42 M | -1.2 M | -1.1 M | -765 K | -672 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.72 K | -5.68 M | -2.69 M |
Quarterly EBITDA NanoVibronix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -1.83 M | - | - | - | - | - | - | - | -1.05 M | - | -923 K | -1.27 M | -1.11 M | - | -867 K | -990 K | -1.31 M | - | -802 K | -1.47 M | -906 K | - | -790 K | -894 K | -2.22 M | - | -1.32 M | -822 K | -788 K | - | -607 K | -655 K | -801 K | - | -539 K | -452 K | -472 K | - | -331 K | -310 K | -309 K | - | -512 K | -265 K | 146 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 146 K | -2.22 M | -844 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
753 M | $ 173.14 | -0.8 % | $ 13 B | ||
|
Bio-Rad Laboratories
BIO
|
421 M | $ 279.25 | 0.63 % | $ 7.88 B | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 10.9 | -1.54 % | $ 1.64 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.17 | -0.41 % | $ 1.64 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.61 | 0.84 % | $ 38 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.3 | -1.79 % | $ 124 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 37.59 | -1.03 % | $ 5.6 K | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 61.79 | 0.83 % | $ 91.5 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.89 | - | $ 1.15 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.0 | -3.86 % | $ 16.9 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 8.68 | -3.12 % | $ 246 M | ||
|
Electromed
ELMD
|
10.7 M | $ 24.12 | -1.19 % | $ 204 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.97 | 0.19 % | $ 375 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.33 | -4.95 % | $ 168 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
LivaNova PLC
LIVN
|
228 M | $ 62.78 | -0.93 % | $ 3.42 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
LENSAR
LNSR
|
-21 M | $ 5.7 | 4.4 % | $ 68.2 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
757 M | $ 90.42 | -1.07 % | $ 12.2 B | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.11 | -0.96 % | $ 870 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
898 K | $ 10.04 | 1.62 % | $ 360 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.69 | -1.43 % | $ 28.9 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 54.02 | -4.71 % | $ 1.59 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.74 | -0.51 % | $ 1.14 B | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 85.11 | -1.8 % | $ 2.96 B | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.68 | 0.38 % | $ 122 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 77.87 | -1.62 % | $ 45.5 B |